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In Brief
Intratumoral STING pathway activation is a promising therapeutic approach to treat cancer. While high doses of STING agonist are effective at clearing injected tumors, Sivick et al. find that lower doses of STING agonist are optimal for generating robust systemic tumorspecific T cell responses and durable anti-tumor immunity.
INTRODUCTION
Induction of tumor-specific CD8 + T cell responses can limit tumor progression; however, CD8 + T cell responses are often evaded or otherwise suppressed, leading to tumor outgrowth (Sharma et al., 2017) . The use of checkpoint inhibitors (CPIs) such as cytotoxic T lymphocyte-associated protein 4 (CTLA4) or programmed death protein 1 (PD-1) can incite tumor regression and durable responses in patients (Ribas and Wolchok, 2018; Sharma and Allison, 2015) . Nevertheless, many patients are refractory to or eventually relapse after checkpoint immunotherapy, necessitating the search for new strategies to boost anti-tumor T cell responses. Stimulator of interferon genes (STING) is required for the spontaneous generation of tumor-specific T cell responses . Natural engagement of STING occurs downstream of cytoplasmic DNA recognition via cyclic guanosine monophosphate (GMP)-AMP (cGAMP) synthetase (cGAS) and generation of the cyclic dinucleotide (CDN) STING ligand 2 0 3 0 cGAMP. After CDN binding by STING, IRF3-and nuclear factor kB (NF-kB)-dependent cytokines are induced . Based on the critical role of the STING pathway in the induction of anti-tumor immunity, CDNs are being explored as a cancer therapy Ng et al., 2018) . The STING agonist dithio-(R P , R P )-[cyclic[A(2 0 ,5 0 )pA(3 0 ,5 0 )p]] (also known as ML RR-S2 CDA, MIW815, or ADU-S100 [S100]) was developed with rational chemical modifications of natural STING ligands to enhance stability and facilitate activation of all five common human STING alleles Yi et al., 2013) , differentiating this compound from others prevalent in the literature. As a single agent, intratumoral (IT) injection of S100 shows potent anti-tumor effects in multiple syngeneic mouse tumor models Foote et al., 2017; Francica et al., 2018) and is under clinical investigation (NCT: NCT02675439 and NCT03172936).
Prior preclinical studies investigating STING-mediated antitumor response reported tumor necrosis factor alpha (TNFa)-mediated injected tumor clearance (Baird et al., 2016; Francica et al., 2018) . Using the clinical compound S100, we explore the mechanistic basis for CD8 + T cell-dependent tumor eradication mediated by IT CDN therapy. We report that the dose of STING agonist affects local activation and systemic expansion of tumor-specific CD8 + T cells in implanted flank mouse models.
By exploring different dosing regimens, we establish that repetitive and/or relatively high doses of S100, while effective in clearing the injected tumor, can diminish tumor-specific T cell responses, negatively affecting durable immunity. Data herein propose a paradigm for STING-driven anti-tumor immunity that necessitates fine-tuning of tumoral STING activation to facilitate interferon (IFN)-driven T cell activation that can synergize with CPIs.
RESULTS

IT STING Activation Can Be Modulated to Induce Local versus Systemic Immune Activation
To optimize the immune response to IT administration of S100, the impact of dose level on the generation of tumor-specific T cells was investigated. Mice bearing a single 4T1 mammary carcinoma flank tumor were treated intratumorally with different doses of S100 three times over the course of one week. Seven days after the third injection, mice treated with 50 mg demonstrated significantly increased tumor-specific T cell responses in peripheral blood, whereas mice treated with vehicle, 100 mg, or 500 mg S100 did not (p = 0.0006) ( Figure 1A ). Because we and others have used multiple-injection STING agonist dosing regimens to achieve tumor clearance (Baird et al., 2016 (Baird et al., , 2017 Demaria et al., 2015; Deng et al., 2014; Foote et al., 2017; Francica et al., 2018) , the impact of dose frequency on induction of tumor-specific T cell responses was also tested. A single 50 mg dose elicited the highest T cell response, while dosing mice repeatedly resulted in significantly lower responses (p = 0.0008 versus 23, p < 0.0001 versus 33) (Figure 1B) . Thus, in mice bearing a single 4T1 tumor, induction of tumor-specific T cells inversely correlated with S100 dose level. To refine the relationship between the dose of S100 and the antitumor response, we titrated the dose of a single S100 IT injection in tumor-bearing mice, comparing acute serum cytokine levels, systemic T cell responses, and primary tumor clearance. Serum cytokine levels and primary tumor clearance correlated with dose level, while the frequency of tumor-specific T cells was highest at the 10 mg dose of S100 and was diminished with higher doses ( Figures 1C, 1D , and S1A). This pattern was recapitulated in the B16.SIY model ( Figure S1B ) (data not shown). While the relationship between dose and cytokine production or injected tumor clearance was roughly linear, the relationship between dose and tumor-specific T cell responses yielded a bell-shaped curve, suggesting that engaging STING with the primary goal of injected tumor clearance leads to selecting a higher-dose regimen than is optimal for the formation of T cell responses. Because IT treatment of STING agonist controls both injected and non-injected tumors (Ager et al., 2017; Demaria et al., 2015; Foote et al., 2017) , we next investigated the effect of dose on immune activation at injected and distal sites. A fundamental question associated with distal tumor activity of STING agonists in mice is whether efficacy in non-injected tumors is attributable to adaptive-mediated immune processes initiated in the injected tumor or to systemic spread of compound that then acts directly in distal tumors. 1 hr after IT administration, we analyzed tumor-resident immune cells for responses to S100. Monocytes from the injected tumor were the predominant cell type producing prototypical STING pathway cytokines TNFa and IFNb ( Figure 1E ). As the dose of S100 increased, so did the frequency of cytokine-positive monocytes and the diversity of responding cell types in the injected tumor ( Figures 1E and S1C ). This pattern of cytokine responsiveness is consistent with monocytic cells being more sensitive to STING activation when compared to lymphocyte subsets, correlating with the level of STING expression in these subsets (Heng et al., 2008; Sivick et al., 2017; Wu et al., 2009 ). In addition, we found that the 500 mg S100 dose produced increased frequencies of TNFa + (p < 0.0001) and IFNb + (p = 0.0108) monocytes in distal tumors ( Figure 1E ). The rapidity with which non-injected tumor cells responded to the 500 mg dose suggests that S100 was directly accessing distal sites. Pharmacokinetic (PK) analyses by mass spectrometry at 30 min after dosing confirmed that significant amounts of S100 were found in distal tumors at the 500 mg dose (134.2 ng/mL ± 29.62), reaching a concentration on the same order of magnitude as tumors injected with 10 mg (923.8 ng/mL ± 371.4) ( Figure 1F ). Thus, administration of low-dose S100 caused local STING activation primarily in monocytic cell lineages and a lack of detectable compound in non-injected tumors, whereas administration of high-dose (E-J) Mice bearing dual-flank 4T1 tumors received one IT injection (in the right flank tumor) with vehicle alone or indicated doses of S100. (E) 1 hr post-injection , both tumors were dissociated and incubated for an additional 4 hr in the presence of Golgi inhibitors for intracellular cytokine staining (ICS) and flow cytometry. Shown are the dot plots of CD11b + Ly-6C hi monocytes stained for TNFa and IFNb (top) and data quantitation (bottom).
(F) 30 min post-injection, S100 levels in the injected and distal tumors were quantitated by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The gray dashed line represents the lower limit of detection multiplied by a dilution factor of five (5 ng/mL). (J) One day post-injection, TDLNs from the injected and distal sides were mounted and stained with Hematoxylin and Eosin (H&E) for histopathological characterization or cleaved caspase-3 (CC3) by IHC. Shown are representative H&E images (top) and automated quantitation of CC3 IHC staining (bottom) (n = 4-5 nodes/group). Vehicle: (A) apoptosis in germinal center within normal levels; 10 mg S100: (A) minimal increased apoptosis in germinal center; 500 mg S100: (A) increased apoptosis, (D) decreased cellularity, and (H) increased histiocytes; scale bar, 200 mm. Data are representative of at least two independent experiments, with n = 5-8 animals/group. Error lines or bars represent the mean ± SEM, and each symbol in bar graphs represents an individual animal. Unless indicated otherwise, significance shown above each bar is compared to vehicle control. ns, not significant; V, vehicle; SFC, spot-forming cells; TDLN, tumor-draining lymph node. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1 . S100 resulted in the presence of CDN and cellular activation at distal sites. To expand our analysis of local versus systemic immune stimulation, T cell activation in both injected and distal tumor-draining lymph nodes (TDLNs) was analyzed three days after IT injection of 10, 100, or 500 mg S100. Activated tumor-specific T cells were found in the injected-side TDLN of mice treated with 10 mg (p = 0.0011) or 100 mg (p = 0.0022) S100, as shown by CD25 and Ki-67 staining on CD8 + AH1 + T cells ( Figures 1G and S1D ).
Tumor-specific CD8 + T cells increased expression of CD11c, granzyme B (GrzB), and Tbet (p < 0.001) (Figures 1H and S1D)-activation markers matching the profile of effector T cells (Pauken et al., 2016) . Consistent with the observed pattern of immunogenicity at day 7 in the blood, there was a lack of T cell activation in the injected TDLN of mice treated with 500 mg S100 (p = not significant [ns] ) and a reduction in the total number of CD8 + T cells (p = 0.0034) ( Figures 1G and 1I ). Meanwhile, activated T cells were detected in the non-injected TDLN of mice treated with 500 mg S100 (p < 0.0001), consistent with an immunogenic dose reaching distal sites ( Figure 1G ). Because the mouse-specific STING agonist DMXAA has been characterized as a vascular disrupting agent (Baguley and Ching, 1997) , one hypothesis for the lack of local T cell activation with higher doses of S100 is that hyperactivation of STING results in tissue damage that prevents T cell trafficking and activation. As an alternative or in addition, cell death could be playing a role, because there are several reports regarding STING activation in connection with various anti-proliferative pathways (Cerboni et al., 2017; Chandra et al., 2014; Gaidt et al., 2017; Gulen et al., 2017; Larkin et al., 2017; Tang et al., 2016; Wu et al., 2014) . To characterize the circumstances leading to dose-dependent inhibition of T cell responses, TDLNs were subjected to immunohistochemical (IHC) and histopathological analyses 24 hr post-IT injection with 10 or 500 mg S100. Injected-side TDLN from mice treated with 10 mg S100 exhibited minimal apoptosis in follicle germinal centers ( Figure 1J ). Conversely, injected-side TDLN from mice treated with 500 mg S100 had moderate to marked increases in apoptosis and decreases in cellularity in different regions of the node, accompanied by increased macrophages in the medullary and paracortical sinus. IHC for cleaved caspase-3 (CC3) showed a dramatic increase in staining in injected TDLN from mice receiving IT injections of 500 mg S100, but not in distal TDLN or TDLN from mice injected with 10 mg S100 ( Figures 1J and S1E ). The dramatic reduction in cellularity and increased CC3 positivity were confirmed by flow cytometry ( Figure S1E ). These results imply that in a mouse with a single-flank tumor, the absence of T cell expansion with either comparatively high or repetitive doses of S100 was due to a lack of T cell activation in the TDLN, presumably due to overt cell death and a compromised infrastructure. Henceforth, we will refer to IT STING activation that can elicit T cell expansion in a single-flank setting as ''immunogenic'' and IT STING activation that can collapse injected tumors but poorly expand T cells as ''ablative.'' These experiments also suggest that in a scenario in which immunogenic doses are distributed to a distal, noninjected tumor site, systemic T cell responses would be preserved during ablative dosing, which is indeed the case (p < 0.0001) ( Figure S1F ).
CD8
+ T Cells Are Necessary and Sufficient for Antitumor Immunity Elicited by Immunogenic Doses of S100 To determine the role of S100-induced CD8 + T cells in tumor control afforded by immunogenic or ablative dosing, mice bearing 4T1 dual-flank tumors were depleted of CD8 + T cells before and after IT injection with S100 ( Figure S2A ). CD8 + T cell depletion prevented the control of injected tumors afforded by an immunogenic dose of S100 (45.7% difference in mean tumor reduction in 10 mg isotype versus aCD8-treated mice, p = 0.0009) (Figures 2A and S2B) . Consistent with our hypothesis that an ablative dose of S100 would eradicate injected tumors independent of cytotoxic T cells, CD8 + T cells were largely dispensable for injected tumor control following ablative dosing (14.6% difference in mean tumor reduction in 500 mg isotype versus aCD8-treated mice, p = ns) (Figures 2A and S2B ).
In keeping with systemic compound distribution ( Figure 1F ) and relocation of CD8 + T cell activation to the lymph node (LN)
draining the non-injected tumor during ablative dosing, CD8 + T cells significantly contributed to distal tumor control after injection of 500 mg S100 (61.7% difference in mean tumor reduction in 500 mg isotype versus aCD8-treated mice, p < 0.0001) (Figures 2A and S2B ).
To investigate whether S100 could elicit durable tumorspecific T cell responses, we rechallenged mice that were cured of their primary tumor with S100 treatment. Mice were given aCD8-depleting or isotype control antibodies, followed by rechallenge with 4T1 tumor cells. In this experiment, a 1 3 100 mg dose was used to increase the cure rate while maintaining some immunogenicity ( Figure 1D ). Compared to naive mice, S100-cured mice were significantly protected from tumor rechallenge, and this protection depended on CD8 + T cells (p < 0.0001) ( Figure 2B ). To examine the effect of dose on protection from rechallenge, mice bearing single-or dual-flank 4T1 tumors were injected with different dosing regimens. Consistent with our findings that ablative dose regimens inhibit tumorspecific T cell responses, mice that cured single-flank tumors with the highest dosing regimen (3 3 500 mg S100) had significantly less protection from rechallenge than mice that received lower dosing regimens (p < 0.0001 versus 3 3 50 mg or 3 3 100 mg) ( Figure 2C ). Mice cured of dual-flank 4T1 tumors by a 3 3 500 mg treatment regimen were protected from rechallenge (8/8 cures), consistent with distribution of immunogenic S100 doses that can elicit durable T cell immunity (p < 0.0001 versus 3 3 500 mg SF) ( Figure S1F ). An appreciable number of mice (6/8) curing primary tumors after 1 3 500 mg S100 were also protected from rechallenge (p < 0.0001 versus naive), though clearance appeared delayed compared to lower dosing regimens ( Figures 2C and S2C ). We attribute protection in the ablative dosing groups to the preexisting pool of tumor-specific T cells resulting from implantation of highly immunogenic 4T1 tumor cells ( Figures 1A, 1B , and 1D, vehicle groups). Consistent with this rationale, we have observed that resection of 4T1 tumors treated with vehicle alone in a survival surgery setting resulted in significant protection against rechallenge (6/8 in one experiment) (data not shown).
Protective immunity afforded by immunogenic or ablative doses of S100 was also tested in an adoptive transfer setting. Supporting the hypothesis that 4T1 tumor-bearing mice harbor (B) Mice bearing a single-flank 4T1 tumor received one IT injection of vehicle alone or 100 mg S100 on day 12. Along with naive controls, mice that cured their primary tumors were injected via the IP route with 100 mg aCD8 (n = 12) or isotype control (n = 11) on days À4 and À2 before implantation with 5 3 10 5 4T1 tumor cells. Shown is the mean rechallenge tumor growth over time (significance on day 25), with the fraction of cured mice indicated in the legend. (C) Mice bearing single-or dual-flank 4T1 tumors received one (13) or three (33) IT injections of 50, 100, or 500 mg S100. Along with naive controls, mice that cured their primary tumors were implanted with 1 3 10 6 4T1 tumor cells. Shown is the mean rechallenge tumor growth over time (significance on day 21), with the fraction of cured mice indicated in the legend. (D) Donor mice bearing a single-flank 4T1 tumor received one IT injection of vehicle alone or 10, 50, or 500 mg S100 on day 9. Seven days post-IT injection, bulk splenocytes or negatively enriched CD8 + cells from donor mice were transferred to naive recipients. Certain cohorts of donor mice were injected via the IP route with 100 mg aCD8 on day À2 and À1 before spleen harvest. One day post-adoptive transfer, naive recipients (n = 5) were implanted with 5 3 10 5 4T1 cells. Shown is the mean tumor growth in recipient mice over time (significance on day 26 on left or day 22 on right), with the fraction of cured mice indicated in the legend. Except for the 500 mg groups in (D), data are representative of at least two independent experiments, with n = 8 animals/group unless indicated otherwise. Error lines represent the mean ± SEM. Unless indicated otherwise, significance is compared to naive control. ns, not significant; SF, single flank; DF, dual flank. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S2 .
an appreciable population of tumor-specific T cells, naive recipient mice receiving CD8 + -enriched cells from vehicle-treated donor animals exhibited a significant delay in tumor growth, although all mice eventually grew tumors (p % 0.001 versus no transfer) ( Figure 2D ). Transfers of either CD8 + -enriched or bulk splenocytes depleted of CD8 + T cells from donor mice given an immunogenic dose of S100 demonstrated CD8 + T celldependent prevention of tumors (S100 50 mg CD8 + enriched: p = 0.0072 versus vehicle CD8 + enriched, 4/5 mice tumor free; S100 10 mg + isotype [iso]: p < 0.0001 versus vehicle + iso, p = 0.0052 versus S100 10 mg + aCD8) ( Figure 2D ). Conversely, splenocytes transferred from donor mice given ablative doses of S100 did not (p = 0.0002 versus vehicle + iso, p = ns versus S100 500 mg + aCD8) ( Figure 2D ). Multiple mechanisms can contribute to protective anti-tumor immunity, as these data reveal that both immunogenic and ablative dosing can delay tumor growth independent of CD8 + T cells ( Figures 2B and 2D) . Nonetheless, these results show that a predominant amount of protective immunity afforded by an immunogenic dose of S100 is driven by CD8 + T cells, and this protection can be compromised by excessive IT STING activation.
Role of Hematopoietic versus Non-hematopoietic Cells in Anti-tumor and Cytokine Responses
To understand the contribution of the hematopoietic and stromal compartments in formation of CD8 + T cell anti-tumor immunity driven by immunogenic doses of S100, bone marrow chimeric mice were generated using wild-type (WT) C57BL/6 and goldenticket (Gt) animals that lack functional STING (Sauer et al., 2011) , creating WT marrow/WT mice, Gt marrow/WT mice, WT marrow/Gt mice, and Gt marrow/Gt mice. At 13 weeks post-transplant, chimerism in recipient mice approached 100% for CD11b + cells and 80%-90% for CD4 + and CD8 + T cells ( Figure S3A ). The resulting sets of mice were implanted with autologous B16.SIY tumor cells lacking STING (B16.SIY STING À/À , to negate any contribution of tumor-associated STING signaling) and treated with an immunogenic dose of S100 ( Figures S1B and S3B ). At seven days post-IT, WT/WT mice had significantly increased numbers of SIY-specific IFNg-secreting cells compared to vehicle controls (p = 0.0004) ( Figure 3A ). T cell responses in Gt/WT mice injected with S100 were low, similar to those of Gt/Gt mice, while responses in WT/Gt mice were similar to those of WT/WT animals (Figure 3A) . Proinflammatory serum cytokine responses detected 6 hr after injection also largely depended on STING signaling in the hematopoietic compartment, though radio-resistant cells appeared to contribute, because WT/Gt mice did not fully recapitulate TNFa and MCP1 levels observed in WT/WT mice (p < 0.0001) ( Figure 3B ). Thus, STING signaling in the hematopoietic compartment contributes to the acute serum cytokine response and is sufficient for S100-mediated boosting of the tumor-specific T cell response.
Type I IFN, but Not TNFa, Is Required for Optimal Antitumor Immune Responses in an Immunogenic Setting CDN IT injection induces both local and systemic cytokines (Figures 1E and S1A ), but the cytokine contribution toward immunogenicity is unclear. To explore the role of TNFa, mice bearing established B16.SIY tumors were dosed with TNFa-neutralizing or isotype control antibodies before IT treatment with an immunogenic dose of S100. As expected, treatment with TNFa-neutralizing antibody resulted in a significant reduction in systemic levels of TNFa, but it also showed a reduction in MCP1 and interleukin-6 (IL-6) (p < 0.0001) ( Figure S4A ). In contrast to tumor models in which repeated dosing of IT STING agonist is required for tumor ablation in a TNFa-dependent manner (Baird et al., 2016; Francica et al., 2018) , blocking TNFa here did not affect tumor clearance ( Figure 4A ). To determine the contribution of type I IFN during immunogenic S100 treatment, mice bearing B16.SIY flank tumors were subjected to treatment with anti-interferon-a/b receptor (aIFNAR) before and during immunogenic S100 IT injection. Neutralizing antibody binding to IFNAR in vivo was confirmed by ex vivo staining and flow cytometry ( Figure S4B ). IFNAR blockade lowered IFNg, IL-6, and MCP1 serum levels, while TNFa was not affected ( Figure S4C ). In this model, signaling through IFNAR was required for tumor control by immunogenic S100 IT therapy (p = 0.0013) ( Figure 4B ), consistent with previous reports using different STING agonists, dose levels, or regimens Demaria et al., 2015) . To probe the IFNAR requirement, CD8 + T cells in the injected-side TDLN were examined 3 days after treatment. In the context of IFNAR blockade, significantly fewer SIY + T cells were detected compared to isotype controls (p = 0.0022), and analysis of the bulk CD8 + T cell population revealed decreased frequencies of Ki-67-, CD11c-, CXCR3-, GrzB-, and Tbet-positive cells ( Figure 4C ). These data reveal that signaling through IFNAR, but not by TNFa, is required for optimal activation and/or differentiation of T cells to an effector phenotype following immunogenic IT dosing of S100.
S100 and aPD-1 Synergize to Control Distal Tumors
Although both immunogenic and ablative doses of S100 elicited a robust tumor-specific CD8 + T cell response in the dual-flank setting ( Figure S1F ), ablative doses could control non-injected tumors, while immunogenic doses could not (Figure 2A ). This result suggested that local STING activation facilitates CD8 + T cell function by modulating the tumor microenvironment (TME). In the absence of systemic drug distribution, we hypothesized that distal tumor control by immunogenic dosing could be potentiated with TME modulation by CPIs. In the 4T1 dual-flank tumor model, aPD-1 exhibited some single-agent activity but did not cure tumors (p = 0.0403) ( Figure 5A ). Combining an immunogenic dose of S100 with systemic aPD-1 elicited near-complete clearance of injected and non-injected tumors (p < 0.005) that depended on CD8 + T cells (p < 0.0001) ( Figures 5A and 5B ).
Thus, combining STING-dependent local T cell priming with aPD-1 resulted in CD8 + T cell-mediated control of distal tumors.
Parallel studies were performed to characterize changes in T cell responses caused by S100, aPD-1, or combination treatment. At day 12 post-IT injection, mice treated with only S100 had trending increases in tumor-specific T cells in the periphery that did not reach significance above that of vehicle-treated mice ( Figure S5 ). However, when combined with aPD-1, the frequency, function (IFNg + TNFa + ), and activation status (CD11c + ) of peripheral AH1 + T cells elicited by S100 were increased (p < 0.05) ( Figure S5 ). Analysis of the distal tumor revealed additional correlates of anti-tumor activity; logically, treatment with aPD-1 decreased PD-1 staining on distal tumor AH1 + T cells (p < 0.0001). S100 alone ostensibly changed the composition and/or activity of tumor-specific T cells, as demonstrated by increases in CD11c and GrzB on CD8 + AH1 + T cells (p < 0.0001) and production of cytokines by CD8 + T cells after AH1 peptide stimulation (p = 0.0007) ( Figure 5C ). These results suggest that S100 activated and expanded tumor-specific T cells, while aPD-1 potentiated the functionality of these cells in the distal TME.
S100, aPD-1, and aCTLA4 Synergize to Elicit Durable Immunity to CPI-Resistant B16 Tumors
To explore durability of immune responses afforded by immunogenic versus ablative dosing regimens in a poorly immunogenic model, mice bearing single-flank B16 tumors refractory to CPI therapy (Lechner et al., 2013) received IT injections with either an immunogenic regimen (1 3 10 mg S100 + aPD-1 + aCTLA4) or an ablative regimen (3 3 100 mg S100). The S100 + aPD-1 + aCTLA4 triple combination elicited significant increases in IFNg-secreting tumor-specific T cells (p % 0.0003 versus S100 + isotype or vehicle + aPD-1 + aCTLA4), while the 3 3 100 mg S100 regimen did not ( Figure 6A ). Survival gains were demonstrated with either immunogenic S100 or CPIs alone compared to vehicle + isotype (p % 0.0005), while the triple combination had a significantly improved survival benefit (p < 0.0001 versus S100 + isotype or vehicle + aPD-1 + aCTLA4) ( Figure 6B ).
Perhaps not surprisingly, the 3 3 100 mg S100 ablative regimen was superior to the triple combination in primary tumor clearance survival (p = 0.0223) ( Figure 6B ). Despite this enticing survival benefit, mice cured using the ablative regimen were not resistant to rechallenge (1/14 cures; p = ns versus naive; Fisher's exact test), while mice curing primary tumors as a result of the triple combination were significantly protected (9/12 cures; p = 0.0013 versus naive, p = 0.0245 versus 3 3 100 mg S100; Fisher's exact test) ( Figure 6C ). In summary, S100 can render poorly immunogenic tumors sensitive to CPI therapy, and combining CPIs with immunogenic doses of S100 resulted in enhancement of tumor-specific T cells and durable anti-tumor immunity.
DISCUSSION
Prior preclinical studies investigating STING-mediated antitumor immunity often focused on dosing regimens that drove TNFa-mediated injected tumor clearance (Baird et al., 2016; Francica et al., 2018) or elicited suboptimal T cell induction and likely did not facilitate true abscopal immunity but instead facilitated systemic distribution of STING agonist (Corrales shown is compared to vehicle control. Data are representative of at least two independent experiments, with n = 8-10 animals/group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S5 . et al., 2015) . We find that a single relatively low dose of IT-administered STING agonist produced the most tumor-specific T cells. In this immunogenic use of STING agonist, T cell responses could be facilitated by STING expression in the hematopoietic compartment, and tumor control was type I IFN dependent, but not TNFa dependent. IFNAR-dependent T cell activation signatures in the TDLN that correlated with protective immune responses in the monotherapy setting were enhanced in the presence of CPIs. Finally, curing tumors by an immunogenic dosing regimen resulted in durable immunity, whereas TNFa--driven tumor ablation did not. With these results, we have developed a working model for IT STING-driven anti-tumor immunity in mice. We found that intensive dosing regimens ablated injected tumors largely without the help of CD8 + T cells (Figure 2 ). Non-CD8 + T cell-mediated tumor clearance may involve innate or cytotoxic mechanisms such as cytokine-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement, and/or direct tumor killing. While innate, cytotoxic, and adaptive mechanisms are not mutually exclusive in either the immunogenic or the ablative setting, the balance among these mechanisms is contextual. For instance, we found that mice curing 4T1 single-flank tumors by the 3 3 100 mg regimen to be resistant to rechallenge, whereas similarly treated mice with B16.F10 tumors were not, perhaps because of differences in immunogenicity of implantation within the tumor models. Additional features of the tumor that may affect IT CDN therapy include protein expression (i.e., STING, neoantigen, checkpoint proteins, and major histocompatibility complex [MHC]), TME infiltration and composition, and tumor size (or overall burden). In addition, aspects of the STING agonist beyond dosing regimen, such as potency, stability, cellular uptake, and affinity for different STING alleles, can influence the outcome of STING activation. While reactogenicity and host cell death can be mitigated and improvements in T cell activation can be made by regimen adjustments (Ager et al., 2017; Chandra et al., 2014) , compounds like S100 that exhibit low intrinsic reactogenicity may provide a broader therapeutic index, considering we observed T cell immunogenicity across a 100-fold dose range in a single 4T1 tumor-bearing animal (Figure 1D) . Understanding STING activation in the context of tumor promotion, as well as regression, is also critical for optimal implementation of CDN treatment (Bose, 2017; He et al., 2017; Ng et al., 2018) , because it was found that chronic STING activation in tumor cells was associated with non-canonical NF-kB pathway activation and metastasis (Bakhoum et al., 2018) . Experiments shown and referenced here demonstrate that IT CDN therapy results in pulsatile STING activation that upregulates canonical NF-kB and IRF3 pathways in host cells and suppresses tumor outgrowth. Thus, rather than promoting metastasis, the net effect of IT therapeutic application of STING agonists is tumor clearance. While the contribution of factors beyond dose are the subject of further investigation, we establish a precedence for achieving durable anti-tumor immunity in which STING activation needs to be tempered to yield maximal Figure 6 . S100, aPD-1, and aCTLA4 Synergize to Elicit Durable Immunity to CPIResistant B16 Tumors
Mice bearing B16 single-flank tumors received one IT injection of vehicle alone or 10 mg S100 or three (33) IT injections of vehicle alone or 100 mg S100 over the course of one week. IT injections were given in the right flank tumor starting on day 10. Indicated cohorts were injected via the IP route with 200 mg of isotype control or aPD-1 and aCTLA4 combined on day 10 and twice weekly thereafter. (C) Along with naive controls, 10 mg S100 + aPD-1 + aCTLA4 or 3 3 100 mg S100 mice that cured their primary tumors were implanted with 2 3 10 5 B16 tumor cells.
Shown is the rechallenge tumor growth for individual animals over time, with the fraction of cured mice indicated in the legend. For (B) and (C), data are the combination of two (3 3 100 mg) or three (remaining groups) independent experiments. *p < 0.05, ***p < 0.001, ****p < 0.0001.
T cell responses, rather than exploited to collapse the primary injected tumor. Experiments using bone marrow chimeric mice revealed that STING signaling in the hematopoietic compartment is sufficient to drive S100-mediated tumor-specific T cell responses (Figure 3) . This result is seemingly in disagreement with Demaria et al. (2015) , who claim that endothelial cells are the main producers of IFNb following IT injection of CDN. One experimental difference that may address this discrepancy is that Demaria et al. (2015) delivered CDN with lipofectamine that presumably facilitates uptake in cell types that may otherwise respond poorly, thereby altering the cellular response profile. Upon ex vivo stimulation of sorted TME cell types, the findings of Corrales et al. (2015) were consistent with myeloid populations, not CD31 + endothelial cells, producing the most IFNb following STING activation. While STING signaling in the stroma was dispensable for the formation of tumor-specific T cell responses in our models, serum cytokines in the WT/Gt mice were significantly lower than those in the WT/WT animals, suggesting that the stromal compartment could contribute to acute cytokine responses. In support of this, chimeric experiments have demonstrated that radio-resistant stromal cells are a key source of TNFa that contributes to collapse of injected tumor in B16.F10 melanoma treated repetitively with 100 mg S100 (Francica et al., 2018) . Consequently, while broad cellular targeting or enhanced induction of NF-kB-dependent cytokines may promote innate-mediated tumor clearance, such conditions may not be ideal for the formation of adaptive anti-tumor responses, because (1) T cell responses in WT/Gt mice trended higher compared to WT/WT mice ( Figure 3A ) and (2) TNFa was dispensable for sustained tumor control when using an immunogenic regimen of S100 (Figure 4) . Future studies will dissect the role of STING signaling in different cellular subsets to further delineate populations responsible for promoting adaptive antitumor immune responses. In addition to STING agonists, activators of alternative innate immune receptors are undergoing clinical evaluation . Because of the broad cellular expression profile and fundamental role in immune cancer surveillance (Woo et al., 2014) , STING may offer advantages as a target for IT therapy. In addition, given the effectiveness by which STING activation can lead to clearance of the injected tumor, one may reason that the clinical objective for IT CDN therapy should be to administer sufficiently ablative doses of CDN to regress injected tumors. For example, oncologists often use chemotherapy to shrink the liver metastases to reduce the tumor burden, which could improve outcomes or make patients eligible for resection (Lé vi et al., 2016) . In this instance, ablative dosing of STING agonist could be an alternative approach for de-bulking and facilitate systemic spread of immunogenic doses to distal tumors. In addition, systemic delivery approaches are attractive when considering the distinct antigenic repertoires between lesions within the same patient. While there is precedence for systemic administration of CDNs in mice (Chandra et al., 2014; Curran et al., 2016) , due to the differences in body size and tolerance to systemic immune activation, distal tumor efficacy achieved through systemic compound distribution and/or very high systemic cytokines in mice is unlikely to translate to humans. Thus, in abscopal response studies in mice, it is necessary to assess whether an effect on a distal lesion is due to systemic drug distribution or a bona fide adaptive response incited by STING activation in the injected tumor. With this in mind, the use of ablative dosing here was intended not to model systemic effects in mice but to probe the consequences of different concentrations of CDN in the tumor, where we believe localized induction of CD8 + T cells may be the most relevant objective. The goal of cancer immunotherapy is to harness the host immune system to destroy tumor cells and elicit durable immunity. CPIs fail in many patients and mouse models, perhaps due to insufficient numbers or inadequate reactivation of tumorspecific T cells. IT STING agonist delivery alters the TME, promoting cellular activation, maturation, and cytokine secretion that results in the expansion of CD8 + T cells (Corrales and Gajewski, 2015; Ng et al., 2018) . Our finding that CDN-checkpoint combinations are beneficial is supported by other groups (Ager et al., 2017; Demaria et al., 2015; Foote et al., 2017; Moore et al., 2016; Wang et al., 2017) . Here, we enrich these findings by showing that distal anti-tumor efficacy elicited by S100 and aPD-1 combination depends on CD8 + T cells and identifying tumor-resident cellular markers that correlate with combination therapy activity ( Figure 5 ). In addition, the finding that mice cured from B16 melanoma by an intensive TNFa-dependent regimen of S100 (Francica et al., 2018) were unable to resist tumor rechallenge suggests that IT injection of ablative doses of STING agonist is detrimental to the formation of immunological memory (Figure 6 ). Based on these findings, there is a logical case to combine immunogenic IT CDN therapy with CPIs to drive efficacious anti-tumor CD8 + T cell responses, and clinical trials combining IT S100 or other STING agonists with aPD-1 are under way (NCT: NCT03172936 and NCT03010176). Collectively, these results establish important principles for application of IT STING agonist therapy and highlight the potential of CPI-STING agonist combinations for the treatment of cancer.
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Tumor Growth All tumor cells were injected subcutaneously into the flank in 100 mL of PBS. Tumor sizes were measured using a digital caliper and tumor volumes calculated with the formula (length x width 2 )/2. Following tumor implantation, mice were randomized into treatment groups. In some experiments, tumor-free survivors were rechallenged with tumor cells on the opposite, non-injected flank several weeks after the collapse of the primary tumor. Naive mice were used as controls.
Adoptive Cell Transfer CD45.1 + BALB/c mice bearing 4T1 tumors were treated with vehicle alone or 10, 50, or 500 mg CDN IT on day 9 after implantation. To deplete CD8 + T cells from a subset of spleens, cohorts of mice were injected the IP route with 100 mg ɑCD8ɑ (clone 2.43, BioXcell) one and two days prior to transfer. Total splenocytes (3x10 In vivo Immunotherapy STING intratumoral (IT) therapy consisted of injecting desired doses of S100 formulated in 40-50 mL of vehicle (HBSS or PBS buffer). IT injections were initiated when tumors grew to between 50-100 mm 3 , one exception being the PK study that was injected when tumors were $400 mm 3 . A 0.3 cc syringe with a 27-gauge needle was filled with test article and all air bubbles removed. Mice were anesthetized with isoflurane. With the bevel facing the skin, the needle was injected shallowly into the area directly adjacent to the tumor, and the needle was moved underneath the skin until it reached the inside back of the tumor. The test article was injected slowly into the center of the tumor. The needle was then removed delicately to avoid reflux. For multiple injection regimens, doses were allocated over the course of one week. Checkpoint blockade therapy consisting of 200 mg of ɑPD-1 (clone RMP1-14, BioXcell), and 200 mg of ɑCTLA-4 (clone 9D9, BioXcell) antibodies alone or in combination, or 200 mg isotype control antibodies (Rat IgG2a and Mouse IgG2b, respectively, BioXcell) was administered on days 10, 13, 16, 20, 24, 28, 32, 36 after implantation with B16 melanoma cells injected subcutaneously. For 4T1 breast cancer studies, mice were treated with 200 mg of ɑPD-1 or isotype control antibody on days 8 or 10, 13, 16, 20, 24, 28, 32, 36 after implantation.
In Vivo Antibody Depletions and Blockade For CD8 + depletion studies, 4T1 tumor bearing mice were treated with 100 mg anti-CD8ɑ monoclonal antibody (clone 2.43, BioXcell) or 100 mg isotype control antibody (Rat IgG1, BioXcell) three times prior and two times after treatment with CDN IT. For depletion prior to rechallenge, 4T1 tumor bearing mice were treated with 100 mg of CDN on day 14 after tumor implantation. Mice that cleared their primary tumor received 100 mg of anti-CD8a or 100 mg of isotype control antibody on days 2 and 4 prior to rechallenge with 0.5 x10 Ex vivo Restimulation Assays T cell responses were accessed by IFNg ELISPOT 7 days after IT injection of vehicle or CDN. Mice were bled in the retro-orbital sinus and PBMCs were isolated from whole blood using Mammal Lympholyte Cell Separation Media (Cedarlane). Spleens were dissociated and treated with ACK Lysis buffer to lyse red blood cells. 1x10 5 PBMCS or 2x10 5 splenocytes were plated per well in X-VIVO media containing 1% penicillin-streptomycin and stimulated overnight with media as a negative control, 1 mM SIY peptide (SIYRYYGL), 1 mM AH1 peptide (SPSYVYHQF, gp70 [423] [424] [425] [426] [427] [428] [429] [430] [431] ), or 1 mM P15e peptide (KSPWFTTL). Spots were developed using a mouse IFNg ELISPOT antibody pair (BD Biosciences) according to the manufacturer's instructions, and the number of spots enumerated using an ImmunoSpot Series 3 Analyzer and ImmunoSpot software (Cellular Technology). T cells were assessed by Intracellular Cytokine Staining (ICS) 12 days after IT injection of vehicle or CDN. Tumors were excised, minced, and homogenized using the gentleMACS Octo Dissociator (Miltenyi). Tumors were digested in media containing 2% Collagenase IV (Worthington), and ultrapure
